Chief Legal Officer & Executive VP of Corporate Affairs Of Ultragenyx Pharmaceutical Sold 39% Of Their Shares

Anyone interested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) should probably be aware that the Chief Legal Officer & Executive VP of Corporate Affairs, Karah Parschauer, recently divested US$441k worth of shares in the company, at an average price of US$45.00 each. That sale was 39% of their holding, so it does make us raise an eyebrow.

See our latest analysis for Ultragenyx Pharmaceutical

The Last 12 Months Of Insider Transactions At Ultragenyx Pharmaceutical

The Independent Director, Matthew Fust, made the biggest insider sale in the last 12 months. That single transaction was for US$620k worth of shares at a price of US$50.89 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$39.05). So it may not tell us anything about how insiders feel about the current share price.

Ultragenyx Pharmaceutical insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

I will like Ultragenyx Pharmaceutical better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Insider Ownership Of Ultragenyx Pharmaceutical

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Ultragenyx Pharmaceutical insiders own 3.0% of the company, currently worth about US$106m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The Ultragenyx Pharmaceutical Insider Transactions Indicate?

Insiders sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. It is good to see high insider ownership, but the insider selling leaves us cautious. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Ultragenyx Pharmaceutical. At Simply Wall St, we found 3 warning signs for Ultragenyx Pharmaceutical that deserve your attention before buying any shares.

Of course Ultragenyx Pharmaceutical may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com